American Journal of Cancer Prevention
Breast cancer is the most common invasive cancer in females worldwide. It accounts for 16% of all female cancers and 22.9% of invasive cancers in women. 18.2% of all cancer deaths worldwide, including both males and females, are from breast cancer. In Western Europe and the United States approximately 1 in 12 women develop breast cancer. A small proportion of breast cancer cases, in particular those arising at a young age, are attributable to a highly penetrant, autosomal dominant predisposition to the disease. Breast cancer rates are much higher in developed nations compared to developing ones. There are several reasons for this, with possibly life-expectancy being one of the key factors - breast cancer is more common in elderly women; women in the richest countries live much longer than those in the poorest nations. The different lifestyles and eating habits of females in rich and poor countries are also contributory factors, experts believe. Breast cancer is often first detected as an abnormality on a mammogram before it is felt by the patient or health care provider.
Breast cancer stages range from early, curable breast cancer to metastatic breast cancer, with a variety of breast cancer treatments. Male breast cancer is not uncommon and must be taken seriously. Surgery and radiation therapy, along with adjuvant hormone or chemotherapy when indicated, are now considered primary treatment for breast cancer. Surgical therapy may consist of lumpectomy or total mastectomy. Radiation therapy may follow surgery in an effort to eradicate residual disease while reducing recurrence rates. Also, hormone therapy and chemotherapy are the 2 main interventions for treating metastatic breast cancer.
The aim of this special issue is evidence-based guidelines on integrated supportive care for breast cancer. This issue welcomes all researchers, academicians, and practitioners on all areas related with breast cancer.
About the issue
The scope of topics covered in the this issue include:
Submission Deadline: April 15, 2015Notification of Acceptance: May 30, 2015Final Version Due: June 15, 2015Special Issue Publishing Date: June 30, 2015
Chief Guest Editor
Masoud SadeghiMedical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, IranEmail: email@example.com
Guest EditorMehrdad PayandehDepartment of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, IranEmail: firstname.lastname@example.org
Ali Shahriari AhmadiDepartment of Oncology and Rheumatology, Rasool Akram Hospital, Tehran, IranEmail: email@example.com
Submit your article now
Manuscripts should be submitted as an attached file to an e-mail directed to the Chief Guest Editor, Masoud Sadeghi at the address: <firstname.lastname@example.org>
or through the journal’s Paper Submission System.